MEDI 8897

Drug Profile

MEDI 8897

Alternative Names: Anti-RSV mAb D25; Anti-RSV MAb-YTE; MEDI-8897; Respiratory syncytial virus monoclonal antibody D25; SP 0232

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AIMM Therapeutics
  • Developer MedImmune
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Respiratory syncytial virus infections

Most Recent Events

  • 03 Aug 2017 Phase-II/III clinical trials in Respiratory syncytial virus infections (In infants, In neonates, Prevention, In volunteers) in United Kingdom, Bulgaria, Czech Republic, Hungary, Italy, South Africa, Spain, USA, Poland, Canada, France (Parenteral) (AIMM Therapeutics pipeline, August 2017)
  • 03 Mar 2017 Sanofi Pasteur and MedImmune agree to co-promote and co-develop MED I8897 for the prevention of Respiratory syncytial virus infections
  • 03 Mar 2017 MedImmune plans a phase III trial for in Respiratory syncytial virus infections (In infants, Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top